MEDICINE COMPOSITION

Publication number: JP8325146 (A)
Publication date: 1996-12-10
Inventor(s): UENO YASUHIKO; SHODA TOMOAKI; SAITOU NAOHIRO
Applicant(s): KYOWA HAKKO KOGYO KK
Classification:
- international: ***A61K9/20; A61K31/00; A61K31/415; A61K45/00; A61K47/12; A61K47/16; A61K47/36; A61P9/00; A61P43/00;*** **A61K9/20; A61K31/00; A61K31/415; A61K45/00; A61K47/12; A61K47/16; A61K47/36; A61P9/00; A61P43/00;** (IPC1-7): A61K31/415; A61K9/20; A61K31/645; A61K45/00; A61K47/12; A61K47/16; A61K47/36
- European:
Application number: JP19950127786 19950526
Priority number(s): JP19950127786 19950526

Also published as:
JP4022269 (B2)

Abstract of **JP 8325146 (A)**

PURPOSE: To obtain a compacted oral administration preparation containing a medicinal substance in a high content, easy in tableting, and excellent in disintegrating, eluting and absorbing properties. CONSTITUTION: 1-80wt.% of a medicinally active ingredient (e.g. thromboxane A2 -antagonizing agent) ground into fine particles having particle sizes of <=30&mu m by a jet grinding method is mixed with a surfactant (e.g. sodium laurylsulfate) in an amount of 1-2wt.% based on that of the medicinally active ingredient or an organic acid salt (e.g. trisodium citrate) in an amount of 0.5-4wt.% based on the medicinally active ingredient, and subsequently formed into nuclear granules. The granules are mixed with a base agent such as starch partially converted into alpha-starch, and subsequently tableted to obtain the objective medicinal composition.; The starch partially converted into the alpha-starch is compounded in an amount of 1-40wt.% based on the medicinally active ingredient. The thromboxane A2 -antagonizing agent is e.g. 11-[2-(5,6-dimethyl-1- benzoimidazolyl)ethylidene]-6,1-dihydrodibenzo[b, e]oxepine-2-carboxylic acid or its salt.